BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7400205)

  • 1. Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects.
    Köpf-Maier P; Hesse B; Voigtländer R; Köpf H
    J Cancer Res Clin Oncol; 1980; 97(1):31-9. PubMed ID: 7400205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].
    Köpf-Maier P; Hesse B; Köpf H
    J Cancer Res Clin Oncol; 1980 Jan; 96(1):43-51. PubMed ID: 7188941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
    Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
    Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor metallocenes: new developments and toxicologic features.
    Köpf-Maier P; Köpf H
    Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice.
    Köpf-Maier P; Moormann A; Köpf H
    Eur J Cancer Clin Oncol; 1985 Jul; 21(7):853-7. PubMed ID: 4043173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of titanocene amino acid complexes.
    Köpf-Maier P; Tornieporth-Oetting IC
    Biometals; 1996 Jul; 9(3):267-71. PubMed ID: 8696077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma.
    Köpf-Maier P; Köpf H
    Arzneimittelforschung; 1987 May; 37(5):532-4. PubMed ID: 3619974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
    Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
    Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
    Köpf-Maier P; Hesse A
    J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.
    Köpf-Maier P; Köpf H
    Naturwissenschaften; 1980 Aug; 67(8):415-6. PubMed ID: 7191057
    [No Abstract]   [Full Text] [Related]  

  • 11. Ionic rhenocene derivatives with antitumor activity.
    Köpf-Maier P; Klapötke T
    Cancer Chemother Pharmacol; 1992; 29(5):361-6. PubMed ID: 1551174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect.
    Köpf-Maier P; Wagner W; Hesse B; Köpf H
    Eur J Cancer (1965); 1981 Jun; 17(6):665-9. PubMed ID: 7308264
    [No Abstract]   [Full Text] [Related]  

  • 13. Titanocene dichloride--the first metallocene with cancerostatic activity.
    Köpf H; Köpf-Maier P
    Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of a Titanocene Dichloride derivative, Ti IV (C5H5)(2) NCS(2), on the haematopoietic response of Ehrlich tumour-bearing mice.
    Valadares MC; Queiroz ML
    Eur J Pharmacol; 2002 Mar; 439(1-3):35-42. PubMed ID: 11937090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.
    Köpf-Maier P
    J Cancer Res Clin Oncol; 1987; 113(4):342-8. PubMed ID: 3036884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
    Köpf-Maier P
    Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ionic titanocene complexes: a new type of antitumor agent.
    Köpf-Maier P; Neuse E; Klapötke T; Köpf H
    Cancer Chemother Pharmacol; 1989; 24(1):23-7. PubMed ID: 2720888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organometallic anticancer agents: the effect of the central metal and halide ligands on the interaction of metallocene dihalides Cp2MX2 with nucleic acid constituents.
    Murray JH; Harding MM
    J Med Chem; 1994 Jun; 37(13):1936-41. PubMed ID: 8027975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis-diamminedichloroplatinum(II) and metallocene dichlorides.
    Köpf-Maier P; Wagner W; Liss E
    J Cancer Res Clin Oncol; 1981; 102(1):21-30. PubMed ID: 7199526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molybdocene dichloride as an antitumor agent (author's transl)].
    Köpf-Maier P; Leitner M; Voigtländer R; Köpf H
    Z Naturforsch C Biosci; 1979 Dec; 34(12):1174-6. PubMed ID: 161840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.